Sanofi's amlitelimab confirms its potential in atopic dermatitis: Paris Saturday, January 24, 2026, 10:00 Hrs [IST] Following the positive COAST 1 (clinical study identifier: NCT0 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback